E Ink participated in the $42.5m first tranche of the gene and protein-focused 3D printing technology developer’s latest round having worked with it on a digital microfluidic tool called eDrop.

UK-based bioprinting technology developer Nuclera reached a $42.5m first close for its series B round yesterday that included electronic paper display producer E Ink, as additive manufacturing gains more attention in the pharmaceutical industry. State-owned financial services firm British Business Bank’s Future Fund also took part in the round, as did M&G Investments, Amadeus Capital…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.